- Conditions
- COVID-19, Vaccine Adverse Reaction, Vaccine Reaction, Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use, Corona Virus Infection, Blood Clot, Thrombocytopenia, Neuritis, Vasculitis, Influenza, Guillain-Barré, GWAS, Genetic Sequencing
- Interventions
- vaccinated
- Biological
- Lead sponsor
- Neuroganics LLC
- Industry
- Eligibility
- 5 Years to 99 Years
- Enrollment
- 100,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Northglenn, Colorado
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Guillain-Barre Syndrome
- Interventions
- Efgartigimod Alfa-Fcab, Intravenous Immunoglobulin (IVIg)
- Drug
- Lead sponsor
- Chafic Karam
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Guillain-Barré Syndrome, Miller Fisher Syndrome
- Interventions
- Not listed
- Lead sponsor
- Erasmus Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Orange, California • New Haven, Connecticut + 19 more
- Conditions
- Guillain-Barre Syndrome
- Interventions
- Tanruprubart
- Drug
- Lead sponsor
- Annexon, Inc.
- Industry
- Eligibility
- 12 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Carlsbad, California + 8 more
- Conditions
- Meningitis, Encephalitis, Guillain-Barré, Subarachnoid Hemorrhage, Intracranial Neoplasm, Intracranial CNS Disorder
- Interventions
- LPat Device
- Device
- Lead sponsor
- Spartanburg Regional Healthcare System
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Spartanburg, South Carolina
- Conditions
- Guillain-Barre Syndrome
- Interventions
- Not listed
- Lead sponsor
- Harvard Pilgrim Health Care
- Other
- Eligibility
- 11 Years to 21 Years
- Enrollment
- 6,000,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 6
- States / cities
- Wilmington, Delaware • Honolulu, Hawaii • Boston, Massachusetts + 3 more